BAKER BROS. ADVISORS LP Q4 2020 Filing
Filed February 16, 2021
Portfolio Value
$26.5B
Holdings
126
Report Date
Q4 2020
Filing Type
13F-HR
All Holdings (126 positions)
| Stock | Value |
|---|---|
SGENUSDSeagen Inc. | $8.3B |
ONCBeiGene, Ltd. | $3.0B |
INCYIncyte Corporation | $2.8B |
ACADACADIA Pharmaceuticals Inc. | $2.2B |
KODKodiak Sciences Inc. | $2.0B |
ALXNAlexion Pharmaceuticals, Inc. | $1.4B |
PRLDPrelude Therapeutics Incorporated | $724.0M |
BMRNBioMarin Pharmaceutical Inc. | $665.5M |
NVTA1EURInvitae Corporation | $654.3M |
ASNDAscendis Pharma A/S | $590.4M |
ABCLAbCellera Biologics Inc. | $420.5M |
MRTXEURMirati Therapeutics, Inc. | $309.6M |
ARGXargenx SE | $299.8M |
1K0IGM Biosciences, Inc. | $277.7M |
MDGLMadrigal Pharmaceuticals, Inc. | $166.7M |
AMRNAmarin Corporation plc | $136.9M |
HRTXHeron Therapeutics, Inc. | $126.9M |
KYMRKymera Therapeutics, Inc. | $121.5M |
ALLKGUSDAllakos Inc. | $100.0M |
CERSCerus Corporation | $94.9M |
BCRXBioCryst Pharmaceuticals, Inc. | $94.6M |
PACBPacific Biosciences of California, Inc. | $83.1M |
—Zymeworks Inc. | $80.7M |
IM8NInsmed Incorporated | $71.8M |
—Forma Therapeutics Holdings, Inc. | $70.7M |
RYTMRhythm Pharmaceuticals, Inc. | $68.8M |
NBIXNeurocrine Biosciences, Inc. | $64.9M |
AXSMAxsome Therapeutics, Inc. | $63.5M |
RAREUltragenyx Pharmaceutical Inc. | $61.5M |
NRIXNurix Therapeutics, Inc. | $58.8M |
BCELAtreca, Inc. | $57.1M |
—Neoleukin Therapeutics, Inc. | $53.9M |
ADAPYAdaptimmune Therapeutics plc | $53.0M |
APLSApellis Pharmaceuticals, Inc. | $51.3M |
KNSAKiniksa Pharmaceuticals, Ltd. | $49.5M |
ADCTADC Therapeutics SA | $45.4M |
ALGSAligos Therapeutics, Inc. | $44.5M |
HZNPHorizon Therapeutics Public Ltd Co | $43.8M |
KRYSKrystal Biotech, Inc. | $41.9M |
CCXIEURChemoCentryx, Inc. | $40.7M |
GBTUSDGlobal Blood Therapeutics, Inc. | $39.9M |
—DBV Technologies S.A. | $38.3M |
OPTEYOpthea Limited | $37.1M |
MRUSMerus N.V. | $35.7M |
ALKSAlkermes plc | $30.6M |
—Frequency Therapeutics, Inc. | $30.2M |
PTGXProtagonist Therapeutics, Inc. | $29.0M |
BCABBioAtla, Inc. | $28.1M |
RETAEURReata Pharmaceuticals, Inc. | $27.7M |
—Athira Pharma, Inc. | $27.6M |
AGLEUSDAeglea BioTherapeutics, Inc. | $26.8M |
FLGTFulgent Genetics, Inc. | $25.8M |
ADPTAdaptive Biotechnologies Corporation | $22.5M |
VSTMVerastem, Inc. | $21.6M |
MREOMereo BioPharma Group plc | $21.6M |
ALTAltimmune, Inc. | $21.3M |
AUPHAurinia Pharmaceuticals Inc. | $19.5M |
IMTXImmatics N.V. | $19.5M |
NVV1Novavax, Inc. | $18.9M |
—Idera Pharmaceuticals, Inc. | $16.9M |
CBAYUSDCymabay Therapeutics, Inc. | $16.6M |
—Invitae Corporation | $16.4M |
XNCRXencor, Inc. | $16.1M |
BMRN 0.599 08/01/24BioMarin Pharmaceutical Inc. | $16.0M |
BDQMAlbireo Pharma, Inc. | $15.5M |
GBYSangamo Therapeutics, Inc. | $13.4M |
—GW Pharmaceuticals plc | $13.0M |
—Gamida Cell Ltd. | $13.0M |
290AChinook Therapeutics, Inc. | $11.9M |
—Five Prime Therapeutics, Inc. | $11.4M |
MIRMMirum Pharmaceuticals, Inc. | $11.3M |
SPRYSilverback Therapeutics, Inc. | $11.0M |
XENEXenon Pharmaceuticals Inc. | $10.6M |
—bluebird bio, Inc. | $9.8M |
OPHTEURIVERIC bio, Inc. | $9.7M |
ASMBAssembly Biosciences, Inc. | $9.3M |
ANABAnaptysBio, Inc. | $9.2M |
CRNXCrinetics Pharmaceuticals, Inc. | $8.7M |
VXRTVaxart, Inc. | $8.0M |
CABACabaletta Bio, Inc. | $7.9M |
HOOKGBPHOOKIPA Pharma Inc. | $7.8M |
—Syros Pharmaceuticals, Inc. | $7.5M |
DNLIDenali Therapeutics Inc. | $7.4M |
KRTXKaruna Therapeutics, Inc. | $7.1M |
AUTLAutolus Therapeutics plc | $7.0M |
HRMYHarmony Biosciences Holdings, Inc. | $6.5M |
—Genetron Holdings Limited | $6.4M |
NTLAIntellia Therapeutics, Inc. | $6.1M |
PASGPassage Bio, Inc. | $6.0M |
REPLReplimune Group, Inc. | $5.9M |
5E7Iteos Therapeutics, Inc. | $5.1M |
TARAProtara Therapeutics, Inc. | $4.8M |
BNRBurning Rock Biotech Limited | $4.8M |
GOSSGossamer Bio, Inc. | $4.6M |
MGNXMacroGenics, Inc. | $4.6M |
1T7Tricida, Inc. | $4.4M |
IFRXInflarx N.V. | $4.3M |
ALECAlector, Inc. | $3.6M |
—LogicBio Therapeutics, Inc. | $3.4M |
—TCR2 Therapeutics Inc. | $3.4M |
Page 1 of 2Next